The ABCC10 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from A-549 human lung adenocarcinoma epithelial cells, engineered to disrupt the ABCC10 gene (encoding MRP7) and provide a loss-of-function model for investigating multidrug resistance mechanisms. This pooled population contains a heterogeneous mix of edited cells, enabling robust functional studies without selecting a single clonal isolate.
A-549 cells, established in 1972 from a 58-year-old Caucasian male with lung adenocarcinoma, are a widely used model for lung cancer biology, drug response, and epithelial cell signaling. These adherent cells retain characteristics of type II alveolar epithelium and are commonly employed in chemosensitivity profiling and transporter studies, making them a suitable platform for dissecting the role of ABCC10 in drug resistance.
ABCC10 (MRP7) is an ATP-binding cassette transporter that actively effluxes lipophilic anticancer agents, including taxanes and vinca alkaloids, as well as endogenous metabolites and glutathione conjugates, thereby reducing intracellular drug accumulation and attenuating apoptosis. The transporter is transcriptionally regulated by nuclear receptors PXR and CAR and the stress-responsive factor NRF2, which drive its expression under conditions of oxidative stress or xenobiotic exposure. ABCC10-mediated efflux is dependent on ATP hydrolysis and is modulated by interactions with scaffolding proteins such as NHERF1/EBP50. In the context of drug resistance, ABCC10 functions as a critical downstream effector that limits the cytotoxic efficacy of structurally diverse chemotherapeutics.
Disruption of ABCC10 in A-549 cells provides a powerful platform to directly assess the contributions of this transporter to acquired and intrinsic drug resistance in lung adenocarcinoma. By eliminating ABCC10 expression, researchers can sensitize cells to substrate drugs and probe the interplay between efflux activity and other resistance mechanisms, such as apoptotic threshold changes. This model is particularly valuable for dissecting NRF2- and PXR/CAR-driven resistance pathways, which are often upregulated in non-small cell lung cancer, and for evaluating the specificity of pharmacological transporter inhibitors.
Typical applications include chemosensitivity assays (e.g., MTT-based viability assays with paclitaxel or vinorelbine), intracellular accumulation measurements of fluorescent substrates like calcein-AM by flow cytometry, Western blotting and RT-qPCR to confirm loss of ABCC10 expression, and immunofluorescence to assess transporter localization or compensatory upregulation of related ABC transporters (e.g., ABCB1, ABCC1). The polyclonal nature reduces the risk of clonal artifacts and provides a more representative response to pharmacological challenges compared to single-cell clones, supporting robust screening of ABC transporter inhibitors and mechanistic studies of multidrug resistance. For further technical information, please contact Ascent Research.
